Accueil・Liste d'Actions・Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings Inc

Fermé

SecteurSoins de santé

35.19 -1.98

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

34.7

Max

35.2

Chiffres clés
By Trading Economics
Revenu	10M 32M
Ventes	-28M 215M
P/E Moyenne du Secteur	14.233 64.641
BPA	0.79
Marge bénéficiaire	15.084
Employés	293
EBITDA	-2.8M 49M

Recommandations
By TipRanks
Recommandations	Achat
Prévisions sur 12 Mois	+15.95% upside

Dividendes
By Acuity
Prochains Résultats	4 août 2026

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	199M 2.1B
Ouverture précédente	37.17
Clôture précédente	35.19

Sentiment de l'Actualité

By Acuity

34%

66%

92 / 340 Classement par Healthcare

Harmony Biosciences Holdings Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

1 août 2026, 00:01 UTC

Shares of Harmony Biosciences Holdings Inc are higher in after-market trading, reflecting notable strength since Friday's close without any specific news driving the move.

31 juil. 2026, 23:21 UTC

Harmony Biosciences Holdings Inc. is trading higher during after-market hours, reflecting steady price increases since Friday's close, despite no specific news identified.

28 juil. 2026, 18:26 UTC

News

Shares of Harmony Biosciences are lower despite a 30% revenue increase for WAKIX, as market sentiment reflects concerns over potential cash flow erosion.

27 juil. 2026, 19:41 UTC

Shares of Harmony Biosciences Holdings Inc. are higher today, breaking from a recent upward trend despite the absence of specific company news.

24 juil. 2026, 17:06 UTC

Shares of Harmony Biosciences Holdings Inc. are lower today, continuing a decline since Thursday's close, despite earlier reaching a session high.

22 juil. 2026, 20:01 UTC

News

Harmony Biosciences Holdings Inc is trading lower despite preliminary Q2 2026 results showing record net product revenue of approximately $261 million, a 30% year-over-year increase.

21 juil. 2026, 21:01 UTC

Harmony Biosciences Holdings Inc. shares are lower in after-market trading, diverging from a broader market rebound despite no specific news driving the decline.

Comparaison

Variation de prix

Harmony Biosciences Holdings Inc prévision

Objectif de Prix

By TipRanks

15.95% hausse

Prévisions sur 12 Mois

Moyen 40.86 USD 15.95%

Haut 55 USD

Bas 29 USD

Basé sur 7 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

7 ratings

Achat

Maintien

Vente

Basé sur 7 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Sentiment

By Acuity

92 / 340Classement par Soins de santé

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.